Multiple individual studies of selective digestive decontamination/selective oropharyngeal decontamination (SDD/SOD) among ICU patients appear to show potent infection prevention effects. Surprisingly, the event rates for multiple endpoints including ventilator-associated pneumonia, bacteraemia and candidaemia among concurrent control groups within SDD/SOD studies appear unusually high versus other rates in the literature. These paradoxical observations raise concern that the contextual effects of SDD/SOD, as postulated in the original SDD/ SOD study, not only exist but also are strong. Until these effects are addressed within an optimally designed study, the safety of SDD/SOD within the 'whole of ICU' remains questionable.
Introduction
Selective digestive decontamination/selective oropharyngeal decontamination (SDD/SOD) regimens appear to have potent activity versus other non-decontamination-based methods in preventing ICU-acquired infections. [1] [2] [3] [4] [5] [6] [7] [8] [9] The earliest study, together with reviews of its underlying theory and early clinical experience of SDD/SOD, have appeared in this journal. 6, 10, 11 The evaluation of SDD/SOD is complex. The SDD/SOD regimens are multi-component. A typical SDD regimen contains polymyxin, an aminoglycoside and amphotericin B. These are applied topically to the oropharynx and via the nasogastric tube. In addition, protocolized parenteral antibiotic prophylaxis (PPAP), most commonly cefotaxime, is administered. A typical SOD regimen is similar in composition but without the nasogastric or PPAP components. However, .20 different SDD/SOD regimens have been described including intensified SDD/SOD regimens for instances of unsuccessful decontamination.
The earliest SDD study by Stoutenbeek et al. 6 targeted trauma patients requiring mechanical ventilation (MV). Recent studies have been less restricted, with a minority of trauma patients in most, and prolonged MV received by only half of the patients in some studies. The optimal duration of application, whether for the duration of MV or longer, is unclear.
The study of SDD/SOD continues to evolve with new regimens and differently defined ICU populations. Studies have employed various types of control groups other than standard care alone. These control group types include the use in addition to standard care of various topical placebos to achieve observer blinding; the PPAP component; or oropharyngeal decontamination using chlorhexidine. The latter comparison is particularly problematic given that the optimal use and safety of chlorhexidine within the ICU population remains uncertain. 12 Moreover, bacteraemia, being less subjective than ventilator-associated pneumonia (VAP), has emerged as a preferred study endpoint. 8, 9 Moreover, from its beginning, Stoutenbeek et al. predicted that '. . . having heavily contaminated patients next to decontaminated patients might adversely affect the potentially beneficial results [postulate 1]. Secondly, a reduction of the number of contagious patients by applying SDD in half of them, might reduce the acquisition, colonisation and infection incidence in the not-SDD-treated control group [postulate 2]'. 13 These contextual effects, being 'whole of ICU', are akin to the herd effects of vaccination, wherein the unvaccinated minority within a population derives benefit (or risk) from the vaccinated majority. The purpose here is to review the SDD/SOD and related literature in an attempt to address this unstudied question. Critically, with these postulated effects of SDD/SOD unanswered, is SDD/SOD safe within the ICU context?
Working definitions
In attempting to address the above question, the operational definition of SDD/SOD used here is any topical antibiotic regimen applied to the oropharynx or upper airway with or without PPAP. The target population is any trauma or general ICU population with the majority receiving prolonged (.24 h) MV. The following groups are excluded here: restricted ICU populations (e.g. cardiac surgery, paediatric, candidaemia risk groups such as liver transplant); group size ,16; and groups from studies of chlorhexidine decontamination. 12 There are 207 studies of SDD/SOD and various other interventions targeting this population (Tables S1-S3,  available or bacteraemia. [1] [2] [3] [4] [5] [6] [7] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] This updates previous literature searches. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Among the 207 studies are three broad categories of study: studies with no intervention (Table S1 ); studies with nondecontamination interventions (Table S2) ; and studies of SDD/SOD as broadly defined above (Table S3 ). There are also three broad categories of control group, those that were concurrent to the SDD/SOD intervention, those that were non-concurrent and those that were concurrent to a non-decontamination intervention. The impact of placebo blinding and use of PPAP in some control groups is discussed elsewhere and not considered here. 27 The non-decontamination interventions (Table S2) 14-26 include interventions such as: use or non-use of different gastric acid inhibitors; [18] [19] feeding by the gastric versus the small bowel route; open versus closed tracheal suction; [20] [21] kinetic bed therapy versus not; 22 subglottic secretion drainage; 23 and various ventilation strategies. [24] [25] [26] Of note, contextual effects have not been postulated for any of the non-decontamination interventions.
SDD/SOD appears to be effective
The apparent superiority of SDD/SOD versus non-decontamination interventions against VAP and bacteraemia is clear in the metaanalyses of these studies (Figures S1 and S2). Among 54 such studies of SDD/SOD (listed in Table S3 ), the effect size (OR; 95% CI) is 0.41; 0.37-0.46 (n " 54; Figure S1 ) against VAP, and 0.69; 0.63-0.76 (n " 40; Figure S2 ) against bacteraemia. In contrast, among 75 studies of non-decontamination interventions (listed in Table  S2 ), the effect size is 0.76; 0.70-0.82 (n " 79; data not shown) against VAP and 1.0; 0.80-1.25 (n " 16; data not shown) against bacteraemia. These effect sizes here are broadly similar to comparable estimates in the literature. [1] [2] [3] [4] [5] [6] [7] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Have indirect (contextual) effects of SDD/SOD been studied?
Several SDD/SOD studies were either cluster randomized or used non-concurrent control groups in an attempt to avoid possible contamination of the effect size by contextual effects (see Figure  S3 ). However, none specifically sought to estimate the postulated contextual effect. One SDD study 38 had a three ICU, two hospital, 24 month, 198 patient, randomized cross-over double blind trial design but was underpowered to test for differences between the concurrent versus non-concurrent control (NCC) groups.
Several studies have examined the 'whole of ICU' prevalence of antimicrobial resistance within ICUs using versus not using SDD/ SOD. One 4 year ecological study of 17 ICUs found a decreasing prevalence of resistance to cefotaxime, ceftriaxone and ciprofloxacin among Gram-negative respiratory isolates but without discernible trends among bacteraemia isolates over 859 cumulative ICU months of SDD/SOD use. 39 The relative proportion of SDD/SOD recipients versus non-recipients among the ICUs in that study is not stated. A sub-analysis of an earlier 13 ICU cluster randomized trial 8 found significantly less respiratory colonization and bacteraemia with highly resistant Gram-negative respiratory isolates during periods of SDD versus periods of standard care. 40 However, a subsequent larger 13 ICU cluster randomized trial conducted in a higher prevalence setting failed to replicate these findings. 41 The discrepancy between these three studies is discussed below.
Benchmarking as a clue to contextual effects
A clue that SDD/SOD might have contextual effects emerges from benchmarking. The mean incidence of VAP (Figure 1a) , bacteraemia ( Figure 1b ) and candidaemia (Figure 1c) for the three categories of control group and two categories of intervention group among the 207 studies are benchmarked versus benchmarks derived from the observational studies (Table S1 ). The methods are as described previously. [29] [30] [31] The data in the plots in Figure 1 (a) and (b) are displayed in more detail as caterpillar plots in Figures  S4-S12 .
In general, the differences, versus each respective benchmark, among the three broad categories of control group are paradoxically greater than those among the two broad categories of intervention group. In each case, the category showing the greatest difference versus each benchmark are the control groups concurrent with an SDD/SOD intervention group with differences versus the respective VAP, bacteraemia and candidaemia benchmarks being 12%, 10% and 0.9%, respectively ( Figure 1 , Table S4 ). These differences versus the benchmark are comparable with the effect sizes attributed to the SDD/SOD intervention.
For VAP and bacteraemia incidences, the high incidence among the category of concurrent control groups of SDD/SOD studies remains apparent within meta-regression models adjusted for several group-level attributes (Table S5) . Moreover, the magnitude of the association with this category of concurrent control group as a term in these models generally equals or exceeds that accounted for by each of the other group-level attributes in the model (Table S5) .
Paradoxical microbiome observations
Benchmarking has been undertaken for VAP in association with Pseudomonas, 34 Acinetobacter, 35 Staphylococcus aureus 33 and Candida 32 as the identified isolates and with Pseudomonas 36 and S. aureus 33 as identified bacteraemia isolates. In each case, the category showing the greatest difference versus each respective benchmark is the category of concurrent control groups within an SDD/SOD study.
Polymyxin, aminoglycosides and antifungals are common constituents of SDD/SOD regimens. This leads to expectations that, among the category of intervention groups of SDD/SOD studies, the mean incidences of VAP where either Pseudomonas, Acinetobacter or Candida are the identified isolate and likewise, the mean incidences of bacteraemia with either Pseudomonas or Acinetobacter, would each be below the respective benchmark. Surprisingly, this is not the case in any of these instances. These observations are paradoxical given both the apparent effect size of SDD/SOD against both VAP ( Figure S1 ) and bacteraemia ( Figure S2 ) as well as the presumed selective action of its constituents on the microbiome.
That the candidaemia incidence for the category of SDD/SOD intervention groups is similar to the benchmark (Figure 1c) is surprising. 31 This is paradoxical as the apparent reduction in fungal carriage among SDD/SOD studies (summary OR 0.12, 95% CI 0.05-0.29) outperforms the reduction effect seen among studies of single antifungal prophylaxis using agents such as fluconazole (summary OR 0.38; 95% CI 0.2-0.7). 42 
For debate
Rebound ICU-acquired Gram-negative bacteraemia arises from intestinal colonization and SDD attenuates this colonization. 43, 44 SDD/SOD is reported to reduce the prevalence of antimicrobial resistance in the respiratory tract over a 4 year observation period. 39 Curiously, a rebound occurs upon the withdrawal of the SDD/SOD intervention. 45 The rebound phenomenon was described in the context of a multicentre SDD/SOD cluster randomized study in which the prevalence of Gram-negative microorganisms resistant to ceftazidime, ciprofloxacin and tobramycin among respiratory and rectal colonization isolates was studied within the whole of ICU (i.e. patients whether or not they were receiving SDD/SOD). 45 With rebound, the prevalence of resistant Gram-negative microorganisms in the post-intervention period was higher than in the baseline period.
Rebound is difficult to understand given the presumed mediation of SDD/SOD. Whether Gram-negative bacteria other than these marker strains, and in particular the antibiotic-susceptible strains, demonstrate a similar rebound is unclear.
Moreover, this 'whole of ICU' phenomenon occurs not only among the SDD/SOD recipients and non-recipients concurrent within the ICU, but persists for several months after SDD/SOD For debate JAC withdrawal. One study found that patients receiving SDD served as reservoirs for persistent Pseudomonas strains in the unit that accounted for the majority of control group Pseudomonas infections. 46 Possibly, intervention patients remaining in the ICU after cessation of the SDD/SOD intervention may, in part, contribute to rebound. Hence it is important to consider the possibility of rebound or other carry-over effects between study periods and the importance of an adequate washout period between cross-over periods of cluster randomized studies. The washout period was 1 month in most instances, but some studies are notable for having no washout period ( Figure S3 ).
Rebound may have been observed elsewhere among studies with apparent prevention effects. Klick et al. 47 examined the use of aerosolized polymyxin as prevention in a placebo-blinded study conducted over 11 alternating placebo and polymyxin cycles without washout periods. This study was 'terminated . . . in the middle of the 11th cycle, a placebo cycle, because of the sudden increase in colonization and infection with P. aeruginosa'. This and other safety concerns contributed to the early abandonment of aerosolized polymyxin in the 1970s. 48 Given the above, could rebound influence the outcomes of even NCC design studies of SDD/SOD? In this regard, the striking difference between two large multi-arm and multicentre clusterrandomized trials of SDD and SOD versus standard care undertaken in several European countries remain unexplained. 8, 41 Reductions in bacteraemia acquired in the ICU seen in the earlier study (5939 patients) 8 with SDD (OR 0.44; 95% CI 0.34-0.57) and with SOD (OR 0.68; 95% CI 0.53-0.86, each versus standard care), were not seen in the larger (8665 patients) study. 41 Of note, 9 of 13 NCC periods within the earlier study 8 followed 6-12 month SDD/SOD intervention periods whereas all NCC periods within the larger study 41 preceded SDD/SOD intervention periods ( Figure S3 ). Plausibly, rebound following SDD/SOD periods could have contaminated the NCC periods in the earlier study, but not the later study. Could such rebound underlie the discrepant results observed, not only for bacteraemia overall but also for the prevalence in antimicrobial resistance? 8, 40, 41 Recommendations for further study It is imperative that the question of the size and direction of the postulated contextual effect of SDD/SOD be clarified to be able to appraise fully its overall effect. This is important not only in relation For debate to claims of any infection prevention effect, but also any mortality effect, [49] [50] [51] and any effect on antimicrobial resistance. Cluster randomization is the standard method where the possibility exists that one study regimen could influence the outcome of another regimen. There are several examples of intervention studies against communicable diseases designed as clusterrandomized trials for this reason. 52, 53 Using this design, one study was able to estimate the herd effect associated with typhoid vaccination. 53 To study Stoutenbeek et al. 13 postulate 2 (SDD/SOD would influence concurrent control patients in the same ICU) would require a three-arm cluster randomized trial (Figure 2 ). There would need to be two control group arms, i.e. one concurrent with the SDD intervention group arm, as well as one non-concurrent, as in the Bergmans et al. 38 study. Such a study would present unique difficulties. A power calculation indicates that 14 clusters each with 400 patients for each arm would be required for 80% power to demonstrate a significant difference of 10% in an endpoint occurring at an incidence of 25% with an intra-cluster correlation of 0.05 (data not shown). The numbers required to detect differences in an endpoint occurring at ,5%, such as the incidence of bacteraemia with a specific antimicrobial resistance, would be substantially greater. Such a study would be overpowered to find differences between the SDD/SOD arm versus either of the two control group arms. Hence, such a study would be difficult to sustain in the face of such a difference emerging, as occurred in the Bergmans et al. 38 study. Moreover, would such a study be ethically acceptable if there is potential for harm to the concurrent control group patients?
Conclusions
The results of the SDD/SOD studies are intriguing. The summary results appear to indicate strong protection against ICU-acquired infection. However, this presumes that the event rates of concurrent control groups were independent of the SDD/SOD intervention. Is this a reasonable assumption for an intervention against infection acquired in the ICU? The first study of SDD/SOD thought not.
13 Until this assumption is tested, the indirect (contextual) effect of SDD/SOD manifesting as herd peril remains a tenable explanation for the apparent protection together with the paradoxical observations. As a consequence, the 'whole of ICU' safety of SDD/SOD in the ICU context remains in doubt. of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13: 665-71.
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